Thor Halfdanarson, Medical Oncologist at the Mayo Clinic, shared a post on X:
“Lu-177 DOTATATE PRRT in patients with NETs and extensive bone metastases. Is it effective and is it safe?
It looks like the answer is yes to both and indeed, we use it frequently under such circumstances. Skeletal related events were 20%…”
Title: Clinical Outcomes of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Skeletal Metastases from Neuroendocrine Tumors: Insights from Real-World Experience
Authors: Kunal Ramesh Chandekar, Swayamjeet Satapathy, Sanjana Ballal, Madhav Prasad Yadav, Shubha Gadde Ravindra, Sameer Rastogi, Ranjit Kumar Sahoo, Chandrasekhar Bal
You can read the Full Article on Journal of Nuclear Medicine.
More posts featuring Thor Halfdanarson.